To achieve this goal, we use patient-specific computational models to predict clinical outcome of currently available and experimental therapies, to find the optimal treatment for each patient.
These models are generated from a combination of clinical data, drug sensitivity assays performed on tumor biopsies, as well as molecular data through partnership with Moffitt's Total Cancer Care and ORIEN/AVATAR initiatives.